Saint-Gobain Life Sciences had used Rx-360 among its own suppliers, but not within its own customer base.
The company enabled this by updating its audit process to include the Rx-360 protocol, as updated by the BioPhorum/Rx-360, as part of development of the Pilot Program.
This joint audit approach was so successful, it is now being rolled out more widely across the business, to support rapid expansion. Key benefits included the ability to licence audit reports – which reduced the burden of audits, resulting in impressive efficiencies. The company also gained increased confidence in the quality of audits – which are tailored to SUS use in the biopharmaceutical sector – and delivered in an efficient manner.
Saint-Gobain Life Sciences’ interest peaked when the company needed to relocate one of its sites in Florida, to accommodate additional lines required for significant growth. This change in address notified to customers, triggered a requirement from them for fresh site audits, and within three months, around 50 companies needed an audit of their new facility.
Leaders knew that they did not have capacity to process 50 additional audits at pace, while managing their own rapid business expansion.
They knew the Rx-360 audit would:
- Enable customers to licence a high-quality audit of their new facility – better than many could perform for themselves
- Respect legal and commercial sensitivities – Some customers are both suppliers and competitors to Saint-Gobain. The system enables completion of valid audit reports, while maintaining organizations’ confidentiality and respecting commercial sensitivities
- Reduce the need for on-site visits – Freeing up the time of Saint-Gobain senior leadership and subject matter experts for redeployment onto other projects
- Better meet the specific needs of the biopharmaceutical industry – with a specific SUS Audit Guide approach
- Accelerate product availability – By allowing more customers to include Saint-Gobain as an approved supplier off the back of the licenced audit report. This helps Saint-Gobain to alleviate supply chain stress for products and enables their release from the new facility.
We found that Rx-360 has a much more comprehensive audit then we would be able to provide to our customers… and also better than most audits that our customers would come in and do.Polly Hanff, Global Regulatory Affairs and Quality Director
Saint-Gobain Healthcare and Life Sciences realized a host of benefits from implementing the updated audit approach, including:
- Reduced burden of administration and site visits – So far, the company has agreed to licence the audit report for its new site 20 times. Estimates suggest the method saved 40 days of Quality personnel’s time, as well as further hours from the Senior Leadership Team and SMEs supporting on-site audits.
- Redeploying staff effort – That time, coupled with hours spent on preparation and follow-ups, can now be redeployed into business growth and innovation.
- Customer access to Saint-Gobain products – The approach enabled products from Saint-Gobain’s facility to be approved for use at a time when the pandemic was severely restricting access to audits. This supported delivery of product from many customers who wouldn’t otherwise have got access to an audit.
- Better ‘trust’ with customers based on the quality of audit reports and the follow up process – The RX-360 provides a robust methodology for the management of audit programs, and any follow-up that may be required, in line with CAPA plans – something many customers are not able to manage as well.
- Saint-Gobain was able to be proactive and manage the situation with an efficient approach to audit processes – offering a better overall service to its customers.
Saint-Gobain Life Sciences’ team tackled several pushbacks relating to the audit program:
Lack of awareness/communication – Despite multiple communications from industry, many end users within Saint-Gobain’s supply chain were unaware of the Joint Audit Program®, or sceptical of the joint audit approach – with some major biopharmaceutical companies initially refusing to take part. There was also a lack of information sharing between different parts of complex global biopharmaceutical companies; Saint-Gobain learned that it had a part to play helping the awareness across its customers’ enterprises.
There were also internal challenges from Saint-Gobain’s own marketing team, which perceived a potential loss of opportunity to showcase its new facilities and capabilities to companies’ auditors during on-site visits. In response, the Saint-Gobain audit team clarified that executive decision makers from the supply chain would not normally attend audits, invalidating this concern.
Saint-Gobain helped to solve both of these communications issues by sharing the materials produced by members of BioPhorum’s Joint Audit Program® workstream, in partnership with Rx-360.
The audit was fantastic. From the very first one we thought ‘Wow’ – our customers can rely on this. It gave me the confidence, as a head within our organization, to feel comfortable now with encouraging our customers to accept this.Polly Hanff, Global Regulatory Affairs and Quality Director